Global Uterine Cancer Therapeutics & Diagnostics Market is segmented based on Product, Cancer Type, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Global Uterine Cancer Therapeutics & Diagnostics Market is segmented based on Product, Cancer Type, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis
Introduction

The Global Uterine Cancer Therapeutics & Diagnostics Market is estimated to be USD 21.16 Bn in 2023 and is expected to reach USD 29.37 Bn by 2028, growing at a CAGR of 6.78%.

Uterine cancer, also known as endometrial cancer, develops in the lining of the uterus. It is the most common gynecologic cancer in women, and its incidence rate is increasing worldwide. The American Cancer Society estimates that the cancer of the uterus in the United States in 2023 to be around 66,200 new cases.

Several types of drugs are used to treat uterine cancer, depending on the cancer stage and other individual factors. Some common drugs used for the treatment of uterine cancer are Chemotherapy drugs, Hormone therapy drugs, Targeted therapy drugs, Immunotherapy drugs, and others.

Several causes, such as Obesity, the background of endometrial, other cancers, hormonal imbalances, endometrial hyperplasia, etc., could cause the rising frequency of uterine cancer. About 70% of uterine cancer cases are linked to obesity. With the increasing rate of obesity and lifestyle diseases, the risk of uterine cancer is anticipated to increase, thereby boosting the market demand.

However, the high cost of therapeutics & diagnostics for uterine cancer hampers the market. In addition, the side effects associated with the therapeutics, such as hair loss, cancer pains, etc., further restrict the market growth.

Advancements in cancer screening and treatment methods are anticipated to create lucrative opportunities for the market. For instance, in 2023, US FDA approved Jemperli's treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer.

Market Segmentations

The Global Uterine Cancer Therapeutics & Diagnostics Market is segmented based on Product, Cancer Type, and Geography.

By Product, the market is classified into Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma. The endometrial adenocarcinoma segment is expected to grow due to the increasing burden of this type of cancer. According to Cancer.gov, endometrial adenocarcinoma is the most common type of uterine cancer in women, accounting for approximately 80% of cases, and the severity can vary. The growing incidence of endometrial carcinoma is linked to increasing rates of obesity among women.

By Cancer Type, the market is classified into Therapeutics and Diagnostics. The Therapeutics segment is increasing due to advances in medical research and the development of new treatments. Targeted therapies and immunotherapy have resulted in treating uterine cancer, and ongoing research is focused on developing new therapies that can further improve patient outcomes.

By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific. Americas segment holds the largest market share in the Global Uterine Cancer Therapeutics & Diagnostics Market. This is due to a combination of factors, including the presence of major market players and well-established healthcare infrastructure. The region has a strong focus on medical research and innovation. Additionally, several initiatives and organizations in the Americas region focus on raising uterine cancer awareness and improving access to screening and treatment.

Recent Development

The FDA approved Jemperli (dostarlimab-gxly) for patients with recurrent or advanced endometrial cancer and the biomarker mismatch repair-deficient. This is the first immunotherapy approved for patients with this type of cancer. - April 2021

FDA Approved Merck’s Keytruda Treatment for Endometrial Carcinoma.- June 2021

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Danaher, Elekta AB, Eli Lilly and Co., F. Hoffmann-La Roche, GSK, etc.

Countries Studied

America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

IGR Competitive Quadrant

The report includes IGR Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global Uterine Cancer Therapeutics & Diagnostics Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

Infogence Global Research analyses the Global Uterine Cancer Therapeutics & Diagnostics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, Infogence Global Research has devised suitable strategies for market growth.

Why buy this report?The report offers a comprehensive evaluation of the Global Uterine Cancer Therapeutics & Diagnostics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.Excel data sheet for the market size will also be provided with the report.The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitorsThe report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.Report Highlights:A complete analysis of the market, including the parent industryImportant market dynamics and trendsImpact Analysis – a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.Market segmentationCompetitive Analysis: Comparative analysis of competitorHistorical, current, and projected size of the market based on value and volumeMarket size of the US statesMarket shares and strategies of key playersRecommendations to companies for strengthening their foothold in the market